Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Introduction: MicroRNAs (miRNAs) are small endogenous non-coding RNAs that repress the expression of their target genes by reducing mRNA stability and/or inhibiting translation. miRNAs are known to be aberrantly regulated in cancers. Modulators of miRNA (mimics and antagonists) have emerged as novel therapeutic tools for cancer treatment.Areas covered: This review summarizes the various strategies that have been applied to correct the dysregulated miRNA in cancer cells. The authors also discuss the recent advances in the technical development and preclinical/clinical evaluation of miRNA-based therapeutic agents.Expert opinion: Application of miRNA-based therapeutics for cancer treatment is appealing because they are able to modulate multiple dysregulated genes and/or signaling pathways in cancer cells. Major obstacles hindering their clinical development include drug delivery, off-target effects, efficacious dose determination, and safety. Tumor site-specific delivery of novel miRNA therapeutics may help to minimize off-target effects and toxicity. Combination of miRNA therapeutics with other anticancer treatment modalities could provide a synergistic effect, thus allowing the use of lower dose, minimizing off-target effects, and improving the overall safety profile in cancer patients. It is critical to identify individual miRNAs with cancer type-specific and context-specific regulation of oncogenes and tumor-suppressor genes in order to facilitate the precise use of miRNA anticancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 1×
“miRNA restoration agents such as miRNA mimics are used to replace the loss of specific miRNAs [4,5].”
MethodA Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626 · cited 1×
“In fact, miRNAs are expressed in a tissue-specific manner, and they play important roles in maintaining tissue identity and function [206].”
BackgroundSi, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y.-Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210083 · Cited by 1,600
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
Medina, P. P., Nolde, M., & Slack, F. J. (2010) · Nature · doi:10.1038/nature09284 · Cited by 1,073 · cited 1×
“The landmark study reporting the phenomenon of ‘oncomiR addition’ in an in vivo model of miR-21-induced pre-B-cell lymphoma [105] advocated the application of miRNA modulation to treat cancer.”
BackgroundA MicroRNA Signature of Hypoxia
Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., Negrini, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01395-06 · Cited by 1,055 · cited 1×
“Interestingly, cancer cells under hypoxic conditions tend to exhibit specific miRNA signature, which collectively stimulate angiogenesis [141,142].”
BackgroundDNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
MicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells
Papagiannakopoulos, T., Shapiro, A., & Kosik, K. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1305 · Cited by 705
Efficient RNA drug delivery using red blood cell extracellular vesicles
Usman, W. M., Pham, T. C., Kwok, Y. Y., Vu, L. T., Ma, V., Peng, B., Chan, Y. S., Wei, L., Chin, S. M., Azad, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04791-8 · Cited by 663
Self-citationHypoxic Radiosensitization: Adored and Ignored
Overgaard, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7878 · Cited by 619
Cited by
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Therapeutic advances of miRNAs: A preclinical and clinical update
Chakraborty, C., Sharma, A. R., Sharma, G., & Lee, S.-S. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2020.08.012 · Cited by 402
“A recent review of the miRNAbased anticancer therapeutics has described the latest miRNA tools for cancer therapy, which is quite promising [29].”
BackgroundRNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
“Restoring miRNA Function in Cancer Since thosemiRNAs play the role as tumor suppressors, restoration of reduced tumor suppressor miRNA function to normal level by miRNA mimics represents a promising cancer treatment strategy (To et al., 2020).”
BackgroundMafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 56
Metadata
- Authors
- To, K. K. W., Fong, W., Tong, C. W. S., Wu, M., Yan, W., & Cho, W. C. S.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2019-11-19
- Volume
- 15
- Issue
- 1
- Pages
- 63-83
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2991573064
- Cited by
- 57
- References
- 15
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments. https://app.cochat.ai/papers/10.1080/17460441.2020.1690449
- The paper
- To, K. K. W., Fong, W., Tong, C. W. S., Wu, M., Yan, W., & Cho, W. C. S. (2020). Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2020.1690449
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.